Insulin resistance and dysglycemia are associated with left ventricular remodeling after myocardial infarction in non-diabetic patients

Cardiovascular Diabetology

Zhen Kun Yang¹  Wei Feng Shen¹  Feng Hua Ding¹  Chen Die Yang¹  Ying Shen¹  Wei Jin¹  Xiao Qun Wang¹  Rui Yan Zhang¹  Lin Lu¹ 

[1] Department of Cardiology, Ruijin Hospital, Shanghai Jiao-Tong University School of Medicine;

关键词: Insulin resistance;    Dysglycemia;    Left ventricular dilation;    Remodeling;    Myocardial infarction;   

DOI  :  10.1186/s12933-019-0904-3

来源: DOAJ

【 摘 要 】

Abstract Background Adverse cardiac remodeling after ST-segment elevation myocardial infarction (STEMI) is a major cause for poor cardiovascular outcomes such as heart failure. The predisposing factors and underlying mechanisms remain not fully understood. This study investigates the association of insulin resistance and dysglycemia with left ventricular (LV) remodeling after STEMI in non-diabetic patients. Methods A total of 485 non-diabetic subjects with STEMI who underwent primary percutaneous coronary intervention were consecutively enrolled and followed up for 12 months. Relation of homeostasis model assessment-estimated insulin resistance (HOMA-IR) and glucose levels to changes in echocardiography parameters was studied. Results Left ventricular dilation was detected in 49.1% of subjects at 12-month follow-up after STEMI, and was more severe in subjects with impaired fasting glucose (IFG), impaired glucose tolerance (IGT) and high HOMA-IR levels. HOMA-IR remained correlated to changes in LV dimensions after adjusting for confounding risk factors. Multivariate regression analysis demonstrated that higher HOMA-IR was independently associated with greater LV dilation after STEMI. A significant interaction term was present between HOMA-IR and IGT in the model (P = 0.001). Conclusions Our study reveals that insulin resistance and dysglycemia are prevalent in non-diabetic patients with STEMI and are predictors of the post-infarction LV dilation. Trial registration Trials number, NCT02089360; registered on March 17, 2014

【 授权许可】

Unknown